Neurosteroid Explained

Neurosteroids, also known as neuroactive steroids, are endogenous or exogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors.[1] [2] The term neurosteroid was coined by the French physiologist Étienne-Émile Baulieu and refers to steroids synthesized in the brain.[3] [4] The term, neuroactive steroid refers to steroids that can be synthesized in the brain, or are synthesized by an endocrine gland, that then reach the brain through the bloodstream and have effects on brain function.[5] The term neuroactive steroids was first coined in 1992 by Steven Paul and Robert Purdy. In addition to their actions on neuronal membrane receptors, some of these steroids may also exert effects on gene expression via nuclear steroid hormone receptors. Neurosteroids have a wide range of potential clinical applications from sedation to treatment of epilepsy and traumatic brain injury.[6] [7] Ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, is under investigation for the treatment of epilepsy.[8]

Classification

See also: List of neurosteroids.

Based on differences in activity and structure, neurosteroids can be broadly categorized into several different major groupings.

Inhibitory neurosteroids

These neurosteroids exert inhibitory actions on neurotransmission. They act as positive allosteric modulators of the GABAA receptor (especially δ subunit-containing isoforms), and possess, in no particular order, antidepressant, anxiolytic, stress-reducing, rewarding,[9] prosocial,[10] antiaggressive,[11] prosexual, sedative, pro-sleep,[12] cognitive and memory-impairing, analgesic,[13] anesthetic, anticonvulsant, neuroprotective, and neurogenic effects.

Major examples include tetrahydrodeoxycorticosterone (THDOC), the androstane 3α-androstanediol, the cholestane cholesterol and the pregnanes pregnanolone (eltanolone), allopregnanolone (3α,5α-THP).[14] [15]

Excitatory neurosteroids

These neurosteroids have excitatory effects on neurotransmission. They act as potent negative allosteric modulators of the GABAA receptor, weak positive allosteric modulators of the NMDA receptor, and/or agonists of the σ1 receptor, and mostly have antidepressant, anxiogenic, cognitive and memory-enhancing, convulsant, neuroprotective, and neurogenic effects.

Major examples include the pregnanes pregnenolone sulfate (PS), epipregnanolone, and isopregnanolone (sepranolone), the androstanes dehydroepiandrosterone (DHEA; prasterone), and dehydroepiandrosterone sulfate (DHEA-S; prasterone sulfate), and the cholestane 24(S)-hydroxycholesterol (NMDA receptor-selective; very potent).[16]

Pheromones

Pheromones are neurosteroids that influence brain activity, notably hypothalamic function, via activation of vomeronasal receptor cells.[17] [18] [19]

Possible human pheromones include the androstanes androstadienol, androstadienone, androstenol, and androstenone and the estrane estratetraenol.

Other neurosteroids

Certain other endogenous steroids, such as pregnenolone,[20] progesterone,[21] [22] estradiol, and corticosterone are also neurosteroids. However, unlike those listed above, these neurosteroids do not modulate the GABAA or NMDA receptors, and instead affect various other cell surface receptors and non-genomic targets. Also, many endogenous steroids, including pregnenolone, progesterone, corticosterone, deoxycorticosterone, DHEA, and testosterone, are metabolized into (other) neurosteroids, effectively functioning as so-called proneurosteroids.

Biosynthesis

Neurosteroids are synthesized from cholesterol, which is converted into pregnenolone and then into all other endogenous steroids. Neurosteroids are produced in the brain after local synthesis or by conversion of peripherally-derived adrenal steroids or gonadal steroids. They accumulate especially in myelinating glial cells, from cholesterol or steroidal precursors imported from peripheral sources.[23] [24] 5α-reductase type I and 3α-hydroxysteroid dehydrogenase are involved in the biosynthesis of inhibitory neurosteroids, while 3β-hydroxysteroid dehydrogenase and hydroxysteroid sulfotransferases are involved in excitatory neurosteroid production.

Function

Some major known biological functions of neurosteroids include modulation of neural plasticity,[25] learning and memory processes,[26] behavior,[27] [28] and seizure susceptibility,[29] as well as responses to stress, anxiety, and depression.[10] [30] Neurosteroids also appear to play an important role in various sexually-dimorphic behaviors and emotional responses.

Acute stress elevates the levels of inhibitory neurosteroids like allopregnanolone, and these neurosteroids are known to counteract many of the effects of stress.[31] This is similar to the case of endorphins, which are released in response to stress and physical pain and counteract the negative subjective effects of such states. As such, it has been suggested that one of the biological functions of these neuromodulators may be to help maintain emotional homeostasis.[32] Chronic stress has been associated with diminished levels of allopregnanolone and altered allopregnanolone stress responsivity, psychiatric disorders, and hypothalamic-pituitary-adrenal axis dysregulation.

It is thought that fluctuations in the levels of inhibitory neurosteroids during the menstrual cycle and pregnancy play an important role in a variety of women's conditions, including premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), postpartum depression (PPD), postpartum psychosis, and catamenial epilepsy.[33] [34] [35] In addition, it is thought that changes in neurosteroid levels may be involved in the changes in mood, anxiety, and sexual desire that occur during puberty in both sexes and during menopause in women.[36] [37]

Elevated levels of inhibitory neurosteroids, namely allopregnanolone, can produce paradoxical effects, such as negative mood, anxiety, irritability, and aggression.[38] [39] [40] [41] This appears to be because these neurosteroids, like other positive allosteric modulators of the GABAA receptor such as the benzodiazepines, barbiturates, and ethanol, possess biphasic, U-shaped actions – moderate levels (in the range of 1.5–2 nM/L total alloprogesterone, which are approximately equivalent to luteal phase levels) inhibit the activity of the GABAA receptor, while lower and higher concentrations facilitate the activity of the receptor.

Biological activity

Sigma-1 receptor

Neurosteroids at the σ1 receptor[42]
Compound Ki (nM) Action Species Ref
268 Antagonist Guinea pig [43] [44]
938 Unknown Guinea pig
1,014 Unknown Guinea pig
Agonist
3,198 Agonist Guinea pig
3,700 Agonist ?
Agonist
4,074 Unknown Guinea pig

Therapeutic applications

Anesthesia

Several synthetic neurosteroids have been used as sedatives for the purpose of general anaesthesia for carrying out surgical procedures. The best known of these are alphaxolone, alphadolone, hydroxydione, and minaxolone. The first of these to be introduced was hydroxydione, which is the esterified 21-hydroxy derivative of 5β-pregnanedione. Hydroxydione proved to be a useful anaesthetic drug with a good safety profile, but was painful and irritating when injected probably due to poor water solubility. This led to the development of newer neuroactive steroids. The next drug from this family to be marketed was a mixture of alphaxolone and alphadolone, known as Althesin. This was withdrawn from human use due to rare but serious toxic reactions, but is still used in veterinary medicine. The next neurosteroid anaesthetic introduced into human medicine was the newer drug minaxolone, which is around three times more potent than althesin and retains the favourable safety profile, without the toxicity problems seen with althesin. However this drug was also ultimately withdrawn, not because of problems in clinical use, but because animal studies suggested potential carcinogenicity and since alternative agents were available it was felt that the possible risk outweighed the benefit of keeping the drug on the market.

Ganaxolone

The neurosteroid ganaxolone, an analog of the progesterone metabolite allopregnanolone, has been extensively investigated in animal models and is currently in clinical trials for the treatment of epilepsy. Neurosteroids, including ganaxolone have a broad spectrum of activity in animal models.[45] They may have advantages over other GABAA receptor modulators, notably benzodiazepines, in that tolerance does not appear to occur with extended use.[46] [47]

A randomized, placebo controlled, 10-week phase 2 clinical trial of orally administered ganaxolone in adults with partial onset seizure demonstrated that the treatment is safe, well tolerated and efficacious. The drug continued to demonstrate efficacy in a 104-week open label extension. Data from non-clinical studies suggest that ganaxolone may have low risk for use in pregnancy. In addition to use in the treatment of epilepsy, the drug has potential in the treatment of a broad range of neurological and psychiatric conditions. Proof-of-concept studies are currently underway in posttraumatic stress disorder and fragile X syndrome. Ganaxolone was approved for medical use in the United States in March 2022.

Catamenial epilepsy

Researchers have suggested the use of so-called "neurosteroid replacement therapy" as a way of treating catamenial epilepsy with neuroactive steroids such as ganaxolone during the period of the menstrual cycle when seizure frequency increases.[48] Micronized progesterone, which behaves reliably as a prodrug to allopregnanolone, has been suggested as a treatment for catamenial epilepsy in the same manner.[49]

Allopregnanolone

Allopregnanolone (SAGE-547) is under development as an intravenous therapy for the treatment of super-refractory status epilepticus, postpartum depression, and essential tremor.[50]

Other applications

4,16-Androstadien-3β-ol (PH94B, Aloradine) is a synthetic pheromone, or pherine, neurosteroid which is under investigation for the treatment of anxiety disorders in women.[51]

3β-Methoxypregnenolone (MAP-4343), or pregnenolone 3β-methyl ether, is a synthetic neuroactive steroid and pregnenolone derivative that interacts with microtubule-associated protein 2 (MAP2) in a similar manner to pregnenolone and is under development for potential clinical use for indications such as the treatment of brain and spinal cord injury and depressive disorders.[52] [53] [54] [55]

Role in antidepressant action

Certain antidepressant drugs such as fluoxetine and fluvoxamine, which are generally thought to affect depression by acting as selective serotonin reuptake inhibitors (SSRIs), have also been found to normalize the levels of certain neurosteroids (which are frequently deficient in depressed patients) at doses that are inactive in affecting the reuptake of serotonin. This suggests that other actions involving neurosteroids may also be at play in the effectiveness of these drugs against depression.[56] [57]

The 3α-hydroxysteroid dehydrogenase (3α-HSD) enzyme is induced by certain (SSRIs), including fluoxetine, fluvoxamine, sertraline, and paroxetine, as well as by certain other antidepressants like venlafaxine and mirtazapine, and these antidepressants have been found to increase inhibitory neurosteroid levels.[58] [59] [60] [61] Enhancement of biosynthesis of inhibitory neurosteroids has been implicated in the antidepressant and anxiolytic effects of some of the SSRIs.

Benzodiazepine effects on neurosteroids

Benzodiazepines may influence neurosteroid metabolism by virtue of their actions on translocator protein (TSPO; "peripheral benzodiazepine receptor").[62] The pharmacological actions of benzodiazepines at the GABAA receptor are similar to those of neurosteroids. Factors which affect the ability of individual benzodiazepines to alter neurosteroid levels may depend upon whether the individual benzodiazepine drug interacts with TSPO. Some benzodiazepines may also inhibit neurosteroidogenic enzymes reducing neurosteroid synthesis.[63]

See also

Further reading

Notes and References

  1. Paul SM, Purdy RH . Neuroactive steroids . FASEB Journal . 6 . 6 . 2311–22 . March 1992 . 1347506 . 10.1096/fasebj.6.6.1347506. 221753076 . free .
  2. Lan NC, Gee KW . Neuroactive steroid actions at the GABAA receptor . Hormones and Behavior . 28 . 4 . 537–44 . December 1994 . 7729823 . 10.1006/hbeh.1994.1052 . 40697424 .
  3. Book: Reddy DS . Neurosteroids . Sex Differences in the Human Brain, their Underpinnings and Implications . Progress in Brain Research . 186 . 113–37 . 2010 . 21094889 . 3139029 . 10.1016/B978-0-444-53630-3.00008-7 . 9780444536303 .
  4. Book: Reddy DS, Rogawski MA . Neurosteroids — Endogenous Regulators of Seizure Susceptibility and Role in the Treatment of Epilepsy . Noebels JL, Avoli M, Rogawski MA . Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US) . 2012 . National Center for Biotechnology Information (US) . 22787590 . https://www.ncbi.nlm.nih.gov/books/NBK98218/. etal.
  5. Srivastava DP, Waters EM, Mermelstein PG, Kramár EA, Shors TJ, Liu F . Rapid estrogen signaling in the brain: implications for the fine-tuning of neuronal circuitry . The Journal of Neuroscience . 31 . 45 . 16056–63 . November 2011 . 22072656 . 3245715 . 10.1523/JNEUROSCI.4097-11.2011 .
  6. Morrow AL . Recent developments in the significance and therapeutic relevance of neuroactive steroids--Introduction to the special issue . Pharmacology & Therapeutics . 116 . 1 . 1–6 . October 2007 . 17531324 . 2047816 . 10.1016/j.pharmthera.2007.04.003 .
  7. Dubrovsky BO . Steroids, neuroactive steroids and neurosteroids in psychopathology . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 29 . 2 . 169–92 . February 2005 . 15694225 . 10.1016/j.pnpbp.2004.11.001 . 36197603 .
  8. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS . Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI) . Epilepsy Research . 103 . 1 . 2–30 . Jan 2013 . 23219031 . 10.1016/j.eplepsyres.2012.10.001 . free .
  9. Rougé-Pont F, Mayo W, Marinelli M, Gingras M, Le Moal M, Piazza PV . The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens . The European Journal of Neuroscience . 16 . 1 . 169–73 . July 2002 . 12153544 . 10.1046/j.1460-9568.2002.02084.x . 9953445 .
  10. Frye CA . Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions . Psychoneuroendocrinology . 34 . Suppl 1 . S143-61 . December 2009 . 19656632 . 2898141 . 10.1016/j.psyneuen.2009.07.005 .
  11. Pinna G, Costa E, Guidotti A . Changes in brain testosterone and allopregnanolone biosynthesis elicit aggressive behavior . Proceedings of the National Academy of Sciences of the United States of America . 102 . 6 . 2135–40 . February 2005 . 15677716 . 548579 . 10.1073/pnas.0409643102 . 2005PNAS..102.2135P . free .
  12. Terán-Pérez G, Arana-Lechuga Y, Esqueda-León E, Santana-Miranda R, Rojas-Zamorano JÁ, Velázquez Moctezuma J . Steroid hormones and sleep regulation . Mini Reviews in Medicinal Chemistry . 12 . 11 . 1040–8 . October 2012 . 23092405 . 10.2174/138955712802762167 .
  13. Patte-Mensah C, Meyer L, Taleb O, Mensah-Nyagan AG . Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain . Progress in Neurobiology . 113 . 70–8 . February 2014 . 23948490 . 10.1016/j.pneurobio.2013.07.004 . 207407077 .
  14. Hénin J, Salari R, Murlidaran S, Brannigan G . A predicted binding site for cholesterol on the GABAA receptor . Biophysical Journal . 106 . 9 . 1938–1949 . May 2014 . 24806926 . 4017285 . 10.1016/j.bpj.2014.03.024 . 2014BpJ...106.1938H .
  15. Levitan I, Singh DK, Rosenhouse-Dantsker A . Cholesterol binding to ion channels . Frontiers in Physiology . 5 . 65 . 2014 . 24616704 . 3935357 . 10.3389/fphys.2014.00065 . free .
  16. Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, Crawford DC, Linsenbardt AJ, Shu HJ, Izumi Y, Mennerick SJ, Zorumski CF . 6 . The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors . The Journal of Neuroscience . 33 . 44 . 17290–17300 . October 2013 . 24174662 . 3812502 . 10.1523/JNEUROSCI.2619-13.2013 .
  17. Book: Hawkes CH, Doty RL . The Neurology of Olfaction. 12 February 2009. Cambridge University Press. 978-0-521-68216-9. 37– .
  18. Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL . The human vomeronasal system . Psychoneuroendocrinology . 19 . 5–7 . 673–86 . 1994 . 7938363 . 10.1016/0306-4530(94)90049-3 . 36129626 .
  19. Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L . Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder . The American Journal of Psychiatry . 171 . 6 . 675–82 . June 2014 . 24700254 . 10.1176/appi.ajp.2014.12101342 . 38510058 .
  20. Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, Strauss JL, Kilts JD . Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence . Neuroscience . 191 . 78–90 . September 2011 . 21756978 . 10.1016/j.neuroscience.2011.06.076 . 26396652 .
  21. Baulieu E, Schumacher M . Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination . Steroids . 65 . 10–11 . 605–12 . 2000 . 11108866 . 10.1016/s0039-128x(00)00173-2 . 14952168 .
  22. Thomas P, Pang Y . Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells . Neuroendocrinology . 96 . 2 . 162–71 . 2012 . 22687885 . 3489003 . 10.1159/000339822 .
  23. Agís-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A . Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis . Proceedings of the National Academy of Sciences of the United States of America . 103 . 39 . 14602–7 . September 2006 . 16984997 . 1600006 . 10.1073/pnas.0606544103 . 2006PNAS..10314602A . free .
  24. Mellon SH, Griffin LD . Neurosteroids: biochemistry and clinical significance . Trends in Endocrinology and Metabolism . 13 . 1 . 35–43 . 2002 . 11750861 . 10.1016/S1043-2760(01)00503-3 . 11605131 .
  25. Benarroch EE . Neurosteroids: endogenous modulators of neuronal excitability and plasticity . Neurology . 68 . 12 . 945–7 . March 2007 . 17372131 . 10.1212/01.wnl.0000257836.09570.e1 . 219216099 .
  26. Vallée M, Mayo W, Koob GF, Le Moal M . Neurosteroids in learning and memory processes . International Review of Neurobiology . 46 . 273–320 . 2001 . 11599303 . 10.1016/s0074-7742(01)46066-1 . 9780123668462 .
  27. Engel SR, Grant KA . Neurosteroids and behavior . International Review of Neurobiology . 46 . 321–48 . 2001 . 11599304 . 10.1016/S0074-7742(01)46067-3. 9780123668462 .
  28. King SR . Emerging roles for neurosteroids in sexual behavior and function . Journal of Andrology . 29 . 5 . 524–33 . 2008 . 18567641 . 10.2164/jandrol.108.005660 . free .
  29. Joshi S, Rajasekaran K, Kapur J . GABAergic transmission in temporal lobe epilepsy: the role of neurosteroids . Experimental Neurology . 244 . 36–42 . June 2013 . 22101060 . 3319002 . 10.1016/j.expneurol.2011.10.028 .
  30. Girdler SS, Klatzkin R . Neurosteroids in the context of stress: implications for depressive disorders . Pharmacology & Therapeutics . 116 . 1 . 125–39 . October 2007 . 17597217 . 2650267 . 10.1016/j.pharmthera.2007.05.006 .
  31. Bali A, Jaggi AS . Multifunctional aspects of allopregnanolone in stress and related disorders . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 48 . 64–78 . Jan 2014 . 24044974 . 10.1016/j.pnpbp.2013.09.005 . 21399549 .
  32. Gunn BG, Cunningham L, Mitchell SG, Swinny JD, Lambert JJ, Belelli D . GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response . Frontiers in Neuroendocrinology . 36 . 28–48 . Jan 2015 . 24929099 . 10.1016/j.yfrne.2014.06.001 . 4349499.
  33. Bäckström T, Andersson A, Andreé L, Birzniece V, Bixo M, Björn I, Haage D, Isaksson M, Johansson IM, Lindblad C, Lundgren P, Nyberg S, Odmark IS, Strömberg J, Sundström-Poromaa I, Turkmen S, Wahlström G, Wang M, Wihlbäck AC, Zhu D, Zingmark E . Pathogenesis in menstrual cycle-linked CNS disorders . Annals of the New York Academy of Sciences . 1007 . 1. 42–53 . December 2003 . 14993039 . 10.1196/annals.1286.005 . 2003NYASA1007...42B . 20995334 . free .
  34. Guille C, Spencer S, Cavus I, Epperson CN . The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment . Epilepsy & Behavior . 13 . 1 . 12–24 . July 2008 . 18346939 . 4112568 . 10.1016/j.yebeh.2008.02.004 .
  35. Finocchi C, Ferrari M . Female reproductive steroids and neuronal excitability . Neurological Sciences . 32 . Suppl 1 . S31-5 . May 2011 . 21533709 . 10.1007/s10072-011-0532-5 . 8885335 .
  36. Genazzani AR, Bernardi F, Monteleone P, Luisi S, Luisi M . Neuropeptides, neurotransmitters, neurosteroids, and the onset of puberty . Annals of the New York Academy of Sciences . 900 . 1. 1–9 . 2000 . 10818386 . 10.1111/j.1749-6632.2000.tb06210.x . 2000NYASA.900....1G . 19302118 .
  37. Melcangi RC, Panzica G, Garcia-Segura LM . Neuroactive steroids: focus on human brain . Neuroscience . 191 . 1–5 . September 2011 . 21704130 . 10.1016/j.neuroscience.2011.06.024 . 10261/61590 . 55704799 . free .
  38. Andréen L, Sundström-Poromaa I, Bixo M, Nyberg S, Bäckström T . Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone . Psychopharmacology . 187 . 2 . 209–21 . August 2006 . 16724185 . 10.1007/s00213-006-0417-0 . 1933116 .
  39. Bäckström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S, Andréen L, Ossewaarde L, van Wingen GA, Turkmen S, Bengtsson SK . Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons . Neuroscience . 191 . 46–54 . September 2011 . 21600269 . 10.1016/j.neuroscience.2011.03.061 . 38928854 .
  40. Andréen L, Nyberg S, Turkmen S, van Wingen G, Fernández G, Bäckström T . Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators . Psychoneuroendocrinology . 34 . 8 . 1121–32 . September 2009 . 19272715 . 10.1016/j.psyneuen.2009.02.003 . 22259026 .
  41. Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G . Allopregnanolone and mood disorders . Progress in Neurobiology . 113 . 88–94 . February 2014 . 23978486 . 10.1016/j.pneurobio.2013.07.005 . 207407084 .
  42. Maurice T, Urani A, Phan VL, Romieu P . The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities . Brain Res. Brain Res. Rev. . 37 . 1–3 . 116–32 . 2001 . 11744080 . 10.1016/s0165-0173(01)00112-6. 44931783 .
  43. Su TP, London ED, Jaffe JH . Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems . Science . 240 . 4849 . 219–21 . 1988 . 2832949 . 10.1126/science.2832949. 1988Sci...240..219S .
  44. Takebayashi M, Hayashi T, Su TP . A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors . Pharmacopsychiatry . 37 . Suppl 3 . S208–13 . 2004 . 15547787 . 10.1055/s-2004-832679 . 260243232 .
  45. Rogawski MA, Reddy DS, 2004. Neurosteroids: endogenous modulators of seizure susceptibility. In: Rho, J.M., Sankar, R., Cavazos, J. (Eds.), Epilepsy: Scientific Foundations of Clinical Practice. Marcel Dekker, New York, 2004;319-355.
  46. Kokate TG, Yamaguchi S, Pannell LK, Rajamani U, Carroll DM, Grossman AB, Rogawski MA . Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice . The Journal of Pharmacology and Experimental Therapeutics . 287 . 2 . 553–8 . November 1998 . 9808680 .
  47. Reddy DS, Rogawski MA . Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself . The Journal of Pharmacology and Experimental Therapeutics . 295 . 3 . 1241–8 . December 2000 . 11082461 .
  48. Reddy DS, Rogawski MA . Neurosteroid replacement therapy for catamenial epilepsy . Neurotherapeutics . 6 . 2 . 392–401 . April 2009 . 19332335 . 2682439 . 10.1016/j.nurt.2009.01.006 .
  49. Book: Devinsky O, Schachter S, Pacia S . Complementary and Alternative Therapies for Epilepsy . 1 January 2005 . Demos Medical Publishing . 978-1-934559-08-6 . 378– .
  50. Web site: Brexanolone - Sage Therapeutics . AdisInsight . Springer Nature Switzerland AG .
  51. Griebel G, Holmes A . 50 years of hurdles and hope in anxiolytic drug discovery . Nature Reviews. Drug Discovery . 12 . 9 . 667–87 . September 2013 . 23989795 . 10.1038/nrd4075 . 4176700.
  52. Web site: Pregnenolone methyl ether - Mapreg . AdisInsight . Springer Nature Switzerland AG .
  53. Duchossoy Y, David S, Baulieu EE, Robel P . Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone . Brain Res. . 1403 . 57–66 . 2011 . 21704982 . 10.1016/j.brainres.2011.05.065 . 42657539 .
  54. Bianchi M, Baulieu EE . 3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders . Proc. Natl. Acad. Sci. U.S.A. . 109 . 5 . 1713–8 . 2012 . 22307636 . 3277154 . 10.1073/pnas.1121485109 . 2012PNAS..109.1713B . free .
  55. Baulieu ÉÉ . From steroid hormones to depressive states and senile dementias: New mechanistic, therapeutical and predictive approaches . Comptes Rendus Biologies . 338 . 8–9 . 613–6 . 2015 . 26251072 . 10.1016/j.crvi.2015.06.003 . free .
  56. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A . Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine . Proceedings of the National Academy of Sciences of the United States of America . 95 . 6 . 3239–44 . March 1998 . 9501247 . 19726 . 10.1073/pnas.95.6.3239 . 1998PNAS...95.3239U . free .
  57. Pinna G, Costa E, Guidotti A . Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake . Psychopharmacology . 186 . 3 . 362–72 . 24 January 2006 . 16432684 . 10.1007/s00213-005-0213-2 . 7799814 .
  58. Book: Reddy. Doodipala Samba. Sex Differences in the Human Brain, their Underpinnings and Implications. Neurosteroids. 186. 2010. 113–137. 0079-6123. 10.1016/B978-0-444-53630-3.00008-7. 21094889. 3139029. Progress in Brain Research. 978-0-444-53630-3.
  59. Griffin LD, Mellon SH . Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes . Proc. Natl. Acad. Sci. U.S.A. . 96 . 23 . 13512–7 . November 1999 . 10557352 . 23979 . 10.1073/pnas.96.23.13512 . 1999PNAS...9613512G . free .
  60. Pinna G . In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis . Behav Pharmacol . 21 . 5–6 . 438–50 . September 2010 . 20716970 . 2942072 . 10.1097/FBP.0b013e32833d8ba0 .
  61. Schüle C, Romeo E, Uzunov DP, Eser D, di Michele F, Baghai TC, Pasini A, Schwarz M, Kempter H, Rupprecht R . Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity . Mol. Psychiatry . 11 . 3 . 261–72 . March 2006 . 16344854 . 10.1038/sj.mp.4001782 . 21473462 .
  62. Dhir A, Rogawski MA . Role of neurosteroids in the anticonvulsant activity of midazolam . British Journal of Pharmacology . 165 . 8 . 2684–91 . April 2012 . 22014182 . 3423249 . 10.1111/j.1476-5381.2011.01733.x .
  63. Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A . Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines . Biological & Pharmaceutical Bulletin . 25 . 4 . 441–5 . April 2002 . 11995921 . 10.1248/bpb.25.441 . pdf . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Neurosteroid".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.